Get the Stockscreener App
26.90
0.37%
0.10
After Hours:
26.90
Arvinas Inc stock is traded at $26.90, with a volume of 269.86K.
It is up +0.37% in the last 24 hours and up +7.77% over the past month.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
See More
Previous Close:
$26.80
Open:
$26.46
24h Volume:
269.86K
Relative Volume:
0.48
Market Cap:
$1.81B
Revenue:
$71.30M
Net Income/Loss:
$-354.80M
P/E Ratio:
-4.8122
EPS:
-5.59
Net Cash Flow:
$-356.00M
1W Performance:
-2.18%
1M Performance:
+7.77%
6M Performance:
-18.04%
1Y Performance:
+53.54%
1-Day Range:
$25.85
$26.94
1-Week Range:
$25.76
$29.61
52-Week Range:
$14.02
$53.08
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
Arvinas's SWOT analysis: biotech stock poised for pivotal trial results - Investing.com
Arvinas's SWOT analysis: biotech stock poised for pivotal trial results By Investing.com - Investing.com UK
Allspring Global Investments Holdings LLC Has $182,000 Stake in Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Arvinas to Participate in Upcoming Investor Conferences - GlobeNewswire
Arvinas (NASDAQ:ARVN) Receives Buy Rating from HC Wainwright - Defense World
Wedbush Issues Pessimistic Estimate for Arvinas Earnings - Defense World
FY2024 EPS Estimates for Arvinas Cut by Leerink Partnrs - Defense World
Arvinas (NASDAQ:ARVN) Price Target Lowered to $40.00 at Oppenheimer - Defense World
Arvinas Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Oppenheimer cuts Arvinas shares price target to $40 ahead of TACTIVE-U trial - Investing.com
Arvinas' (ARVN) Buy Rating Reiterated at HC Wainwright - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Q3 2024 Earnings Call Transcript - Insider Monkey
Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates - MSN
Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Reve - GuruFocus.com
Assenagon Asset Management S.A. Invests $3.44 Million in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ... - Yahoo Finance
Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ... By GuruFocus - Investing.com Canada
Arvinas Reports Progress in Q3 2024 Financials and Trials - TipRanks
Arvinas Inc (ARVN) Q3 2024 Earnings: Revenue Soars to $102.4M, B - GuruFocus.com
Arvinas (NASDAQ:ARVN) Trading 4.3% HigherTime to Buy? - MarketBeat
Arvinas earnings beat by $0.16, revenue topped estimates - Investing.com Canada
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Arvinas Inc (ARVN) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
Arvinas, Inc. (NASDAQ:ARVN) Short Interest Down 12.7% in October - MarketBeat
We're Hopeful That Arvinas (NASDAQ:ARVN) Will Use Its Cash Wisely - Yahoo Finance
Arvinas (ARVN): A Small-Cap Biotech with High Growth Potential - Insider Monkey
Arvinas (ARVN) to Release Earnings on Wednesday - MarketBeat
8 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day - ForexTV.com
SG Americas Securities LLC Sells 76,236 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
'Arvinas stock may double if breast cancer drug beats competition'Stifel By Investing.com - Investing.com South Africa
Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024 - The Manila Times
Arvinas to Report Third Quarter 2024 Financial Results and - GlobeNewswire
(ARVN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Arvinas (NASDAQ:ARVN) pops 11% this week, taking one-year gains to 81% - Simply Wall St
Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause (NASDAQ:ARVN) - Seeking Alpha
Arvinas (NASDAQ:ARVN) Trading 5.9% HigherWhat's Next? - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Sees Significant Decrease in Short Interest - MarketBeat
ESR1-Mutated Metastatic Breast Cancer Market to Rise by 2034 | - openPR
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Millennium Management LLC Decreases Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
A new trading data show Arvinas Inc (ARVN) is showing positive returns. - SETE News
Market Recap Check: Arvinas Inc (ARVN)’s Positive Finish at 25.01, Up/Down 0.04 - The Dwinnex
ARVN underperforms with a -3.03 decrease in share price - US Post News
The Manufacturers Life Insurance Company Sells 24,376 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Trend Tracker for (ARVN) - Stock Traders Daily
Arvinas (NASDAQ:ARVN) Stock Price Up 5.8%Should You Buy? - MarketBeat
Dimensional Fund Advisors LP Buys 29,635 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Market Recap Check: Arvinas Inc (ARVN)’s Negative Finish at 24.48, Up/Down -0.89 - The Dwinnex
Arvinas Inc (ARVN)’s stock price range in the last year - US Post News
Arvinas (NASDAQ:ARVN) Shares Down 3.5% - MarketBeat
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arvinas Inc Stock (ARVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cassidy Sean A | Chief Financial Officer |
Feb 23 '24 |
Sale |
47.05 |
1,702 |
80,079 |
181,916 |
| Peck Ronald | Chief Medical Officer |
Feb 23 '24 |
Sale |
47.05 |
1,699 |
79,938 |
67,516 |
| Taylor Ian | Chief Scientific Officer |
Feb 23 '24 |
Sale |
47.05 |
1,701 |
80,032 |
147,522 |
| Taylor Ian | Chief Scientific Officer |
Jan 04 '24 |
Option Exercise |
16.00 |
8,252 |
132,032 |
109,973 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):